Information on EC 1.3.1.22 - 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+)

New: Word Map on EC 1.3.1.22
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota

EC NUMBER
COMMENTARY hide
1.3.1.22
-
RECOMMENDED NAME
GeneOntology No.
3-oxo-5alpha-steroid 4-dehydrogenase (NADP+)
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
a 3-oxo-5alpha-steroid + NADP+ = a 3-oxo-DELTA4-steroid + NADPH + H+
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
allopregnanolone biosynthesis
-
-
androgen biosynthesis
-
-
Biosynthesis of secondary metabolites
-
-
Brassinosteroid biosynthesis
-
-
cardenolide biosynthesis
-
-
Metabolic pathways
-
-
Steroid hormone biosynthesis
-
-
SYSTEMATIC NAME
IUBMB Comments
3-oxo-5alpha-steroid:NADP+ DELTA4-oxidoreductase
The enzyme catalyses the conversion of assorted 3-oxo-Delta4 steroids into their corresponding 5alpha form. Substrates for the mammalian enzyme include testosterone, progesterone, and corticosterone. Substrates for the plant enzyme are brassinosteroids such as campest-4-en-3-one and (22alpha)-hydroxy-campest-4-en-3-one. cf. EC 1.3.99.5, 3-oxo-5alpha-steroid 4-dehydrogenase (acceptor).
CAS REGISTRY NUMBER
COMMENTARY hide
37255-34-8
-
72412-84-1
-
9029-09-8
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
growth on fermented pistachos, lemons and corn tortillas
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
Sf 9 cell-line
-
-
Manually annotated by BRENDA team
expressed in Arabidopsis thaliana
Swissprot
Manually annotated by BRENDA team
South African clawed frog
-
-
Manually annotated by BRENDA team
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
17-epitestosterone + NADPH
?
show the reaction diagram
-
-
-
-
?
17alpha,21-dihydroxypregn-4-ene-3,11,20-trione + NADPH
17alpha,21-dihydroxy-5alpha-pregnan-3,11,20-trione + NADP+
show the reaction diagram
-
trivial name cortisone
-
ir
17alpha,21-dihydroxypregn-4-ene-3,20-dione + NADPH
17alpha,21-dihydroxy-5alpha-pregnane-3,20-dione
show the reaction diagram
-
-
-
?
17alpha-hydroxyprogesterone + NADPH
17alpha-hydroxy-5alpha-pregnan-3,20-dione + NADP+
show the reaction diagram
-
-
-
-
ir
17beta-methyl-androsta-4,9-dien-3-one + NADPH
17beta-methyl-5alpha-androst-9-en-3-one + NADP+
show the reaction diagram
-
-
-
?
20-alpha-hydroxypregn-4-ene-3one + NADPH
20-alpha-hydroxy-5alpha-pregnan-3-one + NADP+
show the reaction diagram
20alpha-hydroxy-4-pregnen-3-one + NADPH
20alpha-hydroxy-5-beta-pregnan-3-one + NADP+
show the reaction diagram
-
more reactive than progesterone
-
-
?
21-hydroxypregn-4-ene-3,20-dione + NADPH
21-hydroxy-5alpha-pregnan-3,20-dione + NADP+
show the reaction diagram
-
-
-
?
5alpha-pregnan-3,20-dione + NADP+
progesterone + NADPH + H+
show the reaction diagram
-
-
-
-
r
androstenediol + NADPH
5alpha-androstan-3beta,17beta-diol + NADP+
show the reaction diagram
-
-
-
-
ir
androstenedione + NADPH + H+
5alpha-androstan-3,17-dione + NADP+
show the reaction diagram
campestenone + NADPH
5alpha-campestan-3-one + NADP+
show the reaction diagram
reduction at very low levels
-
-
?
cholest-4-en-3-one + NADPH
5-alpha-cholestan-3-one + NADP+
show the reaction diagram
cortexolone + NADPH
17alpha,21-dihydroxy-5alpha-pregnan-3,20-dione + NADP+
show the reaction diagram
-
-
-
-
ir
corticosterone + NADPH + H+
5alpha-dihydrocorticosterone + NADP+
show the reaction diagram
-
-
-
-
?
deoxycorticosterone + NADPH
21-hydroxy-5alpha-pregnan-3,20-dione
show the reaction diagram
epitestosterone + NADPH
?
show the reaction diagram
-
-
-
-
ir
progesterone + NADPH
3alpha-hydroxy-5alpha-pregnan-20-one + NADP+
show the reaction diagram
-
-
-
-
?
progesterone + NADPH
5alpha-pregnan-3,20-dione + NADP+
show the reaction diagram
progesterone + NADPH
5alpha-pregnan-3-20-dione + NADP+
show the reaction diagram
testosterone + NADPH
17beta-hydroxy-5alpha-androstan-3-one + NADP+
show the reaction diagram
testosterone + NADPH
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
testosterone + NADPH
5alpha-dihydrotestosterone + NADP+ + H+
show the reaction diagram
testosterone + NADPH
androstan-3alpha,17beta-diol + androstan-3beta,17beta-diol + 5alpha-dihydrotestosterone
show the reaction diagram
testosterone + NADPH + H+
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
5alpha-pregnan-3,20-dione + NADP+
progesterone + NADPH + H+
show the reaction diagram
-
-
-
-
r
progesterone + NADPH
5alpha-pregnan-3-20-dione + NADP+
show the reaction diagram
testosterone + NADPH
17beta-hydroxy-5alpha-androstan-3-one + NADP+
show the reaction diagram
testosterone + NADPH
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
additional information
?
-
-
role of enzyme in initiation of spermatogenensis
-
-
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
coenzyme Q10
-
-
NADP+
-
-
additional information
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
K+
-
stimulate
Li+
-
stimulate
Mg2+
-
stimulatory at concentration 1 mM
additional information
-
not dependent on divalent cation
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-methysticin
-
-
(+/-)-LY191704
-
i.e. (4aS,10aR)-7-chloro-1-methyl-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-one, non-steroidal, most potent benzoquinoline mimicing 4-azasteroid inhibitors, and specific for isozyme 5alphaR-1, IC50 is 30 nM
(-)-epigallocatechin-3-gallate
-
i.e. EGCG, from Thea sativa, slightly inhibits the liver microsomal enzyme
(10bR)-8-chloro-4,10b-dimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform II, 49% inhibition at 0.02 mM
(10bR)-8-chloro-4,5,10b-trimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform II, 57% inhibition at 0.029 mM
(10bR)-8-chloro-5,10b-dimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform II, 42% inhibition at 0.03 mM
(2E,4E,6E,8E)-((2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate
-
compound shows moderate anti-tumour activity in vivo
(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl palmitoate
-
activity of 3-O-acylated (e)-epigallocatechins increases with the increasing carbon numbers of the fatty acid moiety, reaching maximum for palmitoate
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(1,3,5-benzotrioxepin-6-ylmethyl)tetrahydrofuran-2-ol
-
-
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(1,3,5-benzotrioxepin-7-ylmethyl)tetrahydrofuran-2-ol
-
i.e. (-)-cubebin
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(2,3-dimethoxybenzyl)tetrahydrofuran-2-ol
-
-
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(3,4-dimethoxybenzyl)tetrahydrofuran-2-ol
-
i.e. (-)-3,4-dimethoxy-3,4-desmethylenedioxycubebin
(4aS)-7-chloro-4a-methyl-2,3,4,4a-tetrahydrophenanthrene-2-carboxylic acid
-
-
(4aS,10bS)-4,10b-dimethyl-8-[(E)-2-naphthylylvinyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 6 nM, isoform II, 50% inhibition at 0.00134 mM
(4aS,10bS)-4,10b-dimethyl-8-[(E)-2-phenylvinyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 6 nM, isoform II, 50% inhibition at 0.0014 mM
(4aS,10bS)-4,8-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 11 nM
(4aS,10bS)-8-(2-furyl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 59 nM, isoform II, 50% inhibition above 10 nM
(4aS,10bS)-8-bromo-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 35 nM
(4aS,10bS)-8-chloro-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 60 nM
(4aS,10bS)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 17 nM
(4aS,10bS)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 8 nM, isoform II, 50% inhibition above 0.01 mM
(4aS,10bS)-8-fluoro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 35 nM
(4aS,10bS)-8-methoxy-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 120 nM
(4R)-4,8-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 312 nM
(4R)-8-chloro-4-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 141 nM
(4S)-4,8-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 137 nM
(5'S)-17beta-(2-chlorophenyl-4,5-dihydrooxazol-5-yl)androst-5-en-3-one
-
-
(5'S)-17beta-(4-bromophenyl-4,5-dihydrooxazol-5-yl)androst-5-en-3-one
-
-
(5alpha,20-R)-4-Diazo-21-hydroxy-20-methylpregnan-3-one
-
RMI18,341
(6R)-8-chloro-6-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 188 nM
(Z)-((2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl) hexadec-9-enoate
-
-
1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 298 nM
1-methyl-5-(4-(2-phenylacetyl)phenyl)pyridin-2(1H)-one
-
61% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
10-azasteroids
-
several
11-ketoprogesterone
-
complete inhibition
17-diisopropylcarbamoyl-2-androsten-3-carboxylate
-
-
17-diisopropylcarbamoyl-3,5-androstadien-3-carboxylate
-
-
17-diisopropylcarbamoyl-3-androsten-3-carboxyate
-
-
17-diisopropylcarbamoyl-androstan-3-carboxylate
-
-
17-tert-butylcarbamoyl-3,5-androstadien-3-carbaldehyde
-
-
17-tert-butylcarbamoyl-3,5-androstadien-3-carboxylate
-
dead-end inhibition versus testosterone
17-tert-butylcarbamoyl-3,5-androstadien-3-ol
-
-
17a-(2-propionoxyethyl)-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 100% inhibition; 0.01 mM, 8.5% inhibition
17a-allyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 0.4% inhibition; 0.01 mM, 99% inhibition
17a-ethyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 100% inhibition; 0.01 mM, 32.3% inhibition
17a-methyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 18.9% inhibition; 0.01 mM, 99% inhibition
17alpha-hydroxyprogesterone
-
-
17alpha-methyltestosterone
-
-
17alpha-p-bromophenylcarbamoyloxy-4-pregnen-3 20-dione
17alpha-p-bromophenylcarbamoyloxy-4-pregnen-3,20-dione
17alpha-phenylcarbamoyloxy-4-pregnen-3,20-dione
17beta-(N-tert-butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
-
-
17beta-Carbamoyl-1,3,5(10)-estratriene-3-carboxylic acids
17beta-estradiol
17beta-hydroxyandrosta-1,4-dien-3-one
-
50% inhibition
17beta[3-(N-4-bromophenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-chlorophenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-ethoxyphenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-ethylphenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-methoxyphenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-phenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-tolyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
slight inhibition
19-norandrost-4-ene-3,17-dione
-
complete inhibition
19-nortestosterone
-
complete inhibition
2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
-
-
2-(16-(acetylthio)hexadecanamido)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamido)hex-4-enoate
-
43% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
2-(2-(16-(acetylthio)hexadecanamido)ethoxy)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamido)hex-4-enoate
-
33% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
20alpha-hydroxypregn-4-en-3-one
-
competitive
21,21-pentamethylene-4-aza-5alpha-pregn-1-ene-3,20-dione
-
i.e. L685,273, suppresses testicular enzyme activity during puberty by 75-86%
3-Androstene-3-carboxylic acids
3beta-(3'-oxapentanoyloxy)-androst-5-en-17-one
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
3beta-acetoxyandrost-5-en-17-one
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
3beta-hexanoyloxyandrost-5-en-17-one
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
4,16-androstadien-3-one
-
-
4,6,8-trimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 15.8 nM
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 20 nM
4-(1-[4-[acetyl(methyl)amino]-3-methylphenyl]-1-ethylpropyl)-2-methylphenyl diethylcarbamate
-
22% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]-3-methylphenyl]-1-ethylpropyl)phenyl diethylcarbamate
-
25% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)-2-methylphenyl diethylcarbamate
-
56% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl 4-methylpiperazine-1-carboxylate
-
17% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl azepane-1-carboxylate
-
70% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl azocane-1-carboxylate
-
20% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl bis(1-methylethyl)carbamate
-
72% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl bis(1-methylpropyl)carbamate
-
22% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dibenzylcarbamate
-
51% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dibutylcarbamate
-
32% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl diethylcarbamate
-
57% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dimethylcarbamate
-
29% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dipropylcarbamate
-
77% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl morpholine-4-carboxylate
-
15% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl piperidine-1-carboxylate
-
68% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl pyrrolidine-1-carboxylate
-
57% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-methylethyl)phenyl diethylcarbamate
-
16% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-propylbutyl)phenyl diethylcarbamate
-
27% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]cyclobutyl)phenyl diethylcarbamate
-
16% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]cycloheptyl)phenyl diethylcarbamate
-
25% inhibition at 0.01 mM; 46% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]cyclopentyl)phenyl diethylcarbamate
-
5% inhibition at 0.01 mM
4-(2-[5-[(diphenylmethyl)carbamoyl]-1-benzofuran-2-yl]phenoxy)butanoic acid
-
isoform I, 50% inhibition at 310 nM, isoform II, 50% inhibition above 0.1 mM
4-(2-[6-[(diphenylmethyl)carbamoyl]-1-benzofuran-2-yl]phenoxy)butanoic acid
-
isoform I, 50% inhibition at 62 nM, isoform II, 50% inhibition at 270 nM
4-(3-(4-(N-methylacetamido)phenyl)pentan-3-yl)phenyl dibenzylcarbamate
-
competitive inhibitor
4-(4'-formylphenoxy)benzoic acid
4-(biphenyl-4'-yloxy)phenylacetic acid
4-(biphenyl-4'-yloxy)phenylformic acid
4-(N-(diphenyl)acetyl-4-piperidinyloxy)benzoic acid
4-(N-(diphenyl)carbamoyl-4-piperidinyloxy)benzoic acid
4-(N-(tert-butyloxycarbonyl)-4-piperidinyloxy)benzoic acid
4-(N-adamantanoyl-4-piperidinyloxy)benzoic acid
4-Androsten-3-one-17beta-carboxylic acid
-
competitive
4-Aza-4-methyl-5alpha-pregnane-3,20-dione
4-azasteroids
4-bromo-17alpha-(p-fluorobenzoyloxy)-4-pregnene-3,20-dione
-
competitive
4-carboxy-4'-(N,N-dicyclohexyl)-aminobiphenyl
4-carboxy-4'-(N,N-diisobutyl)-aminobiphenyl
4-carboxy-4'-(N,N-diisopropyl)-aminobiphenyl
4-carboxy-4'-(N,N-diphenyl)-aminobiphenyl
4-carboxy-4'-(N-adamantyl)-aminobiphenyl
4-Ene-3-keto-steroids
-
17beta-estradiol in high concentrations functions as an uncompetitive inhibitor
4-MA
active at 0.01 mM
4-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 185 nM
4-methyl-4-azasteroids
4-methyl-5,6-dihydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 1400 nM
4-methyl-azasteroid
4-[1-[4-(acetylamino)-3-methylphenyl]-1-ethylpropyl]-2-methylphenyl diethylcarbamate
-
17% inhibition at 0.01 mM
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
isoform I, 50% inhibition at 50 nM, isoform II, 50% inhibition at 340 nM
4-[2-(6-[[bis(4-methoxyphenyl)methyl]amino]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
isoform I, 50% inhibition at 42 nM, isoform II, 50% inhibition at 480 nM
4-[2-(6-[[bis(4-methoxyphenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
isoform I, 50% inhibition at 130 nM, isoform II, 50% inhibition at 930 nM
4-[3-[(2,2-diphenyl-1,3-benzodioxol-5-yl)oxy]-2-methyl-1H-indol-1-yl]butanoic acid
-
isoform I, 50% inhibition at 10 nM, isoform II, 50% inhibition at 6300 nM
5alpha-androstane-3,17-dione
-
30% inhibition
5beta-cholestan-3-one
-
-
6,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 14.3 nM
6-azasteroids
-
several
6-methylene-17alpha-(2-cyclohexylacetoxy)-pregn-4-ene-3,20-dione
-
-
6-methylene-17alpha-(3-cyclohexylpropionyloxy)-pregn-4-ene-3,20-dione
-
-
6-methylene-17alpha-(3-cyclopentylpropionyloxy)-pregn-4-ene-3,20-dione
-
-
6-methylene-17alpha-(4-cyclohexylbutyryloxy)-pregn-4-ene-3,20-dione
-
-
6alpha-methyl-11-ketoprogesterone
-
25% inhibition
6beta-methyl-11-ketoprogesterone
-
50% inhibition
7-bromo-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
-
-
7-chloro-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
-
-
8-bromo-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 60 nM, isoform I
8-chloro-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 49 nM
8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 460 nM, isoform I
8-chloro-1-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 204 nM
8-chloro-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 459 nM
8-chloro-4,5-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 15.6 nM
8-chloro-4,6-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 8.5 nM
8-chloro-4-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 7.6 nM
8-chloro-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 30 nM, isoform I
8-chloro-5-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 346 nM
8-chloro-6-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 14.4 nM
8-fluoro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 600 nM, isoform I
8-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 376 nM
8-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 176 nM
acrylate episteride
AFA131
active at 0.01 mM
AFA192
active at 0.01 mM
AFA27
active at 0.01 mM
AFA76
active at 0.01 mM, most potent inhibitor among non-steroid compounds tested
alpha-4-azasteroids
-
substitution of finasteride N-group by 6-azasteroids increased the rate of inhibition of type-1 5-alpha-reductases
androst-1-ene-3,17dione
-
55% inhibition
androst-4-en-3,17-dione
-
-
androst-4-ene-3,17-dione
-
complete inhibition
androst-4-enedione
-
-
AS601811
active at 0.01 mM
asclepic acid
-
50% inhibition at 0.50 mM
benzoquilizin-3-ones
-
diverse, mimics of 10-azasteroids, overview, structure-activity relationships
benzoquinolines
-
compounds as mimics of 4-azasteroid inhibitors, diverse, overview, compounds derived from 6-azasteroids, overview
beta-sitosterol
-
-
Biochanin A
-
-
Cd2+
-
1 mM: less than 20% inhibition
cholest-5-en-3-one
-
-
cholestanone
-
-
dehydroepiandrosterone
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
deoxycorticosterone acetate
-
competitive
Detergents
-
e.g.: Lubrol WX, Nonidet P-40, octyl D-glucopyranoside, L-alpha-lysophosphatidylcholine, CHAPS, concentration-dependent inhibition
dihydrotestosterone
-
significantly decreases 5alpha-R1 mRNA and 5alpha-R2 mRNA expression in female rats
docosanol
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
dutasteride
EDTA
-
slightly inhibitory
epristeride
-
-
estradiol
-
in female genital skin fibroblasts
estradiol-17beta
ethinylestradiol
finasteride
FK143
-
i.e. 4-[3-(3-[[bis-(4-isobutyl-phenyl)-methyl]amino]-benzoyl)-indol-1-yl]-butyric acid, a non-steroidal bi-substrate inhibitor
flavins
-
and flavin analogs, high concentration
-
genistein
-
-
ginsenoside Rg3
-
a unique ginsenoside in red ginseng
ginsenoside Ro
kaikasaponin III
-
0.1 mM, 66.8% inhibition
lauric acid
-
isoform 1, 50% inhibition at 0.0167 mM, isoform 2, 50% inhibition at 0.0186 mM
lauric acid ethyl ester
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
linoleic acid
LY306089
-
a non steroid, non-competitive inhibitor of type I 5alpha-reductase in DU145 cells
MK434
-
-
Mn2+
-
1 mM: less than 20% inhibition
myristic acid
-
isoform 2, 50% inhibition at 0.004 mM
N(dicyclohexyl)acetylpiperidine-4-(2-methoxybenzylidene-4-carboxylic acid)
-
isoform 1, pH 6.6, 37C, 55% inhibition at 0.01 mM, isoform 2, pH 5.5, 37C, 43% inhibition at 0.01 mM
N,N-bis(1-methylethyl)-4-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzamide
-
isoform I, 50% inhibition at 510 nM, isoform II, 9% inhibition at 0.01 mM
N,N-dicyclohexyl-4-(4'-carboxyphenoxy)benzamide
N,N-diisobutyl-4-(4'-carboxyphenoxy)benzamide
N,N-diisopropyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide
-
8% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N,N-diisopropyl-2-(4-(1-methyl-6-oxopiperidin-3-yl)phenoxy)acetamide
-
6% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N,N-diisopropyl-2-(4-(2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)phenoxy)acetamide
-
3% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N,N-diisopropyl-4-(4'-carboxyphenoxy)benzamide
N,N-diphenyl-4-(4'-carboxyphenoxy)benzamide
N-(1-adamantanoyl)piperdine-4-(2-methoxybenzyliden-4-carboxylic acid)
N-(1-adamantanoyl)piperidine-4-(2-fluorobenzylidene-4-carboxylic acid)
N-(3,3-diphenyl)propanoylpiperidine-4-(benzylidene-4-carboxylic acid)
N-(dicyclohexyl)acetylpiperidine-4-(2-fluorobenzylidene-4-carboxylic acid)
N-(dicyclohexyl)acetylpiperidine-4-(2-methoxybenzylidene-4-carboxylic acid)
-
pH 5.5, 37C, DU145 cells, 5% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.00013 mM
N-(dicyclohexyl)acetylpiperidine-4-(benzylidene-3-carboxylic acid)
N-(dicyclohexyl)acetylpiperidine-4-(benzylidene-4-acetic acid)
N-(dicyclohexyl)acetylpiperidine-4-(benzylidene-4-carboxylic acid)
N-(diphenyl)acetylpiperidine-4-(2-fluorobenzylidene-4-carboxylic acid)
N-(diphenyl)acetylpiperidine-4-(2-methoxybenzylidene-4-carboxylic acid)
N-(diphenyl)acetylpiperidine-4-(benzylidene-3-carboxylic acid)
N-(diphenyl)acetylpiperidine-4-(benzylidene-4-acetic acid)
N-adamantyl-4-(4'-carboxyphenoxy)benzamide
N-allyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide
-
6% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N-allyl-2-(4-(2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)phenoxy)acetamide
-
8% inhibition of type 1 steroid 5alpha reductase at 0.01 mM and 12% inhibition of type 2 steroid 5alpha reductase at 0.01 mM
N-cyclohexyl-4-(4'-carboxyphenoxy)benzamide
N-phenyl-4-(4'-carboxyphenoxy)benzamide
N-tert-butyl-4-(4'-carboxyphenoxy)benzamide
non-steroidal bi-substrate inhibitors
-
several, structures, overview
-
oleic acid
oleic acid ethyl ester
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
ONO 3805
-
-
ONO-3805
-
a non-steroidal bi-substrate inhibitor
p-chloromercuribenzoate
palmitic acid
PD17
active at 0.01 mM
PD91
active at 0.01 mM
penta-O-galloyl-beta-D-glucose
Piper betle ethanolic whole plant extract
-
42.3% inhibition at 2 mg/ml
-
Piper cueba ethanolic fruit extract
-
28.0% inhibition at 2 mg/ml
-
Piper kadsura ethanolic leaf extract
-
19.0% inhibition at 2 mg/ml
-
Piper kadsura ethanolic rhizome extract
-
36.5% inhibition at 2 mg/ml
-
Piper kadsura ethanolic root extract
-
39.2% inhibition at 2 mg/ml
-
Piper kadsura ethanolic stem extract
-
16.9% inhibition at 2 mg/ml
-
Piper longum ethanolic whole plant extract
-
12.3% inhibition at 2 mg/ml
-
Piper methysticum ethanolic leaf extract
-
28.4% inhibition at 2 mg/ml
-
Piper methysticum ethanolic rhizome extract
-
42.5% inhibition at 2 mg/ml
-
Piper methysticum ethanolic stem extract
-
21.9% inhibition at 2 mg/ml
-
Piper nigrum ethanolic fruit extract
-
63% inhibition at 2 mg/ml
-
Piper nigrum ethanolic leaf extract
-
53.0% inhibition at 2 mg/ml
-
Piper nigrum ethanolic stem extract
-
40.8% inhibition at 2 mg/ml
-
piperine
-
-
progesterone
riboflavin
-
-
sitosterol
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
SKF105657
-
a steroidal type II 5alpha-reductase specific inhibitor
soyasaponin I
-
0.1 mM, 66.8% inhibition
stearic acid
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
steroid carboxylic acid compounds
-
diverse, tricyclic aryl acid mimics of, overview
testosterone
theaflavin-3'-gallate
-
i.e. TF2b, from Thea sativa, inhibits the liver microsomal enzyme
theaflavin-3,3'-digallate
theaflavin-3-gallate
-
i.e. TF2a, from Thea sativa, inhibits the liver microsomal enzyme
tocopherol
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
turosteride
Unsaturated 3-carboxysteroids
VG106
active at 0.01 mM
yangonin
-
-
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
2-mercaptoethanol
-
3fold activity at 1 mM
3beta-acetoxy-16alpha-17alpha-epoxy-4-pregnen-20-one
-
-
3beta-acetoxy-5,16-pregnadien-20-one
-
-
4-pregnen-17-ol-3-one
-
-
androstandione
-
in male foreskin fibroblasts
androstenedione
-
in male foreskin fibroblasts
dihydrotestosterone
-
significantly increases 5alpha-R1 mRNA and 5alpha-R2 mRNA expression in male rats
dilauroylphosphatidylcholine
-
marked stimulatory effect on activity
dithiothreitol
iodoacetamide
-
stimulatory on solubilized enzyme from microsomes
morphine
-
morphine significantly reduces the testosterone concentration after acute and chronic exposure in the spinal cord. In contrast, the 5alpha-reductase 1 expression and of course dihydrotestosterone levels increase tfollowing chronic morphine administration
N-ethylmaleimide
-
stimulatory on solubilized enzyme from microsomes
Oxytocin
-
increases activity in human prostate epithelial cells
phosphatidylserine
-
4fold increase in activity
Phospholipids
-
stimulate
sulpiride
-
40 mg/kg doses induce mRNA expression of 5alphaR1 and 5alpha-R2; 40 mg/kg doses induce mRNA expression of 5alphaR1 and 5alpha-R2
testosterone
-
in female genital skin fibroblasts
additional information
-
oxytocin does not stimulate enzyme activity or expression in human prostate epithelial cells
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00057 - 0.00078
17-epitestosterone
0.00086
20alpha-hydroxypregn-4-en-3-one
-
-
0.0002 - 0.0005
20alpha-hydroxyprogesterone
0.0004 - 0.02634
androstenedione
0.000569 - 0.018
corticosterone
0.14
cortisone
-
-
0.00102 - 0.65
NADPH
0.000095 - 0.12
progesterone
0.0000013 - 0.0446
testosterone
additional information
additional information
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000006
(+)-LY191704
-
-
0.000004
(-)-LY191704
-
-
0.00092
(10bR)-8-chloro-4,10b-dimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform I
0.0011
(10bR)-8-chloro-4,5,10b-trimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform I
0.00026 - 0.0012
(4aS)-7-chloro-4a-methyl-2,3,4,4a-tetrahydrophenanthrene-2-carboxylic acid
0.000035
(5alpha,20-R)-4-Diazo-21-hydroxy-20-methylpregnan-3-one
-
at 25C formation of the reversible EI complex is not rate-limiting for enzyme inactivation, and this is expressed as saturation kinetics for the inhibition reaction
0.000085
17-diisopropylcarbamoyl-2-androsten-3-carboxylate
-
-
0.000007 - 0.000018
17-diisopropylcarbamoyl-3,5-androstadien-3-carboxylate
-
-
0.00003
17-diisopropylcarbamoyl-3-androsten-3-carboxyate
-
-
0.0022
17-diisopropylcarbamoyl-androstan-3-carboxylate
-
-
0.0045
17-tert-butylcarbamoyl-3,5-androstadien-3-carbaldehyde
-
-
0.000033
17-tert-butylcarbamoyl-3,5-androstadien-3-carboxylate
-
-
0.0042
17-tert-butylcarbamoyl-3,5-androstadien-3-ol
-
-
0.000036 - 0.0093
17beta-(N-tert-butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
0.026 - 0.036
17beta-estradiol
0.146
17beta-hydroxyandrosta-1,4-diene-3-one
-
-
0.000315 - 0.01
2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
0.00006
20alpha-hydroxypregn-4-en-3-one
-
-
0.0049
4,16-androstadien-3-one
-
-
0.0000058
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I
0.0000062 - 0.0000118
4-Aza-4-methyl-5alpha-pregnane-3,20-dione
0.0126
4-bromo-17alpha-(p-fluorobenzoyloxy)-4-pregnene-3,20-dione
-
pH 6.0, 25C
0.000002 - 0.0000084
4-methyl-azasteroid
0.000026 - 0.01
7-bromo-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
0.00032 - 0.0025
7-chloro-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
0.0000027
8-chloro-4-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I
0.0000003 - 0.0041
acylate episteride
0.0000043 - 0.000017
dutasteride
0.000001 - 0.005
finasteride
0.000004
LY306089
-
-
0.0031
MK434
-
-
0.0043 - 0.0319
NADP+
0.00048 - 0.0027
penta-O-galloyl-beta-D-glucose
0.00086
progesterone
-
-
0.0026 - 0.0065
theaflavin-3'-gallate
0.00036 - 0.0056
theaflavin-3,3'-digallate
additional information
additional information
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00003
(+/-)-LY191704
Homo sapiens
-
i.e. (4aS,10aR)-7-chloro-1-methyl-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-one, non-steroidal, most potent benzoquinoline mimicing 4-azasteroid inhibitors, and specific for isozyme 5alphaR-1, IC50 is 30 nM
0.00076
(2E,4E,6E,8E)-((2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.00053
(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl palmitoate
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.44
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(1,3,5-benzotrioxepin-6-ylmethyl)tetrahydrofuran-2-ol
1.03
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(2,3-dimethoxybenzyl)tetrahydrofuran-2-ol
0.00072
(5'S)-17beta-(2-chlorophenyl-4,5-dihydrooxazol-5-yl)androst-5-en-3-one
Rattus norvegicus
-
pH 7.3, 37C
0.00105
(5'S)-17beta-(4-bromophenyl-4,5-dihydrooxazol-5-yl)androst-5-en-3-one
Rattus norvegicus
-
pH 7.3, 37C
0.00048
(Z)-((2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl) hexadec-9-enoate
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.000026
17a-(2-propionoxyethyl)-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
Homo sapiens
P18405, P31213
pH not specified in the publication, 37C
0.000073
17a-allyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
Homo sapiens
P18405, P31213
pH not specified in the publication, 37C
0.000022
17a-ethyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
Homo sapiens
P18405, P31213
pH not specified in the publication, 37C
0.000054
17a-methyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
Homo sapiens
P18405, P31213
pH not specified in the publication, 37C
0.00005
17alpha-p-bromophenylcarbamoyloxy-4-pregnen-3 20-dione
0.00001
17alpha-phenylcarbamoyloxy-4-pregnen-3,20-dione
Homo sapiens
-
in the presence of 1 mM dithiothreitol, in 40 mM sodium phosphate buffer, at pH 6.5; with 1 mM dithiothreitol in 40 mM sodium phosphate buffer, at pH 6.5 and 37C
0.0000011
3beta-(3'-oxapentanoyloxy)-androst-5-en-17-one
Homo sapiens
-
pH 6.5, 37C
0.0000052
3beta-acetoxyandrost-5-en-17-one
Homo sapiens
-
pH 6.5, 37C
0.000000002
3beta-hexanoyloxyandrost-5-en-17-one
Homo sapiens
-
pH 6.5, 37C
0.00084
4-(3-(4-(N-methylacetamido)phenyl)pentan-3-yl)phenyl dibenzylcarbamate
Homo sapiens
-
-
0.14
Biochanin A
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.000025
dehydroepiandrosterone
Homo sapiens
-
pH 6.5, 37C
0.37
equol
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.81
ethinylestradiol
Rattus norvegicus
-
-
0.000008 - 0.008
finasteride
0.71
genistein
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.086
ginsenoside Rg3
Rattus norvegicus
-
pH 7.2, 37C
0.259
ginsenoside Ro
Rattus norvegicus
-
pH 7.2, 37C
0.0005
MK386
Homo sapiens
-
-
0.48
piperine
Rattus norvegicus
-
-
0.017
riboflavin
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.000000012
-
activity in dark grown cultures is slightly higher than in light grown cultures
0.00014
-
extract from shoot culture
0.00148
-
female
0.00234
-
male
0.03413
-
female
0.34
-
with NADPH
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5.2 - 5.6
-
mutant G34R
5.5 - 7.5
-
-
5.5
-
isozyme 2, low substrate concentration, efficiency optimum Vmax/Km
5.7
-
in testis microsomes of 5 month-old animals
5.8 - 7.5
-
-
6 - 6.5
-
mutant P181L
6.2
-
female
6.3
-
in testis microsomes of 6 month-old animals
7 - 9
-
human: 2 forms, 1. pH-optimum 5.5 (only in fibroblasts derived from genital skin), 2. pH-optimum 7-9 (in both genital and nongenital skin regions and in fibroblast from all skin regions)
7.3 - 7.6
-
-
8
-
recombinant monkey 5alpha-reductase isozyme 1
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
4.5 - 9
-
recombinant human 5alpha-reductase isozyme 1
4.5 - 9.5
-
recombinant human 5alpha-reductase isozyme 2
4.5 - 7.5
-
recombinant monkey 5alpha-reductase isozyme 2
4.5 - 9
-
pH .5: about 30% of activity maximum, pH 9.0: about 20% of activity maximum
5 - 8
-
pH 5.0: about 20% of activity maximum, pH 8.0: about 20% of activity maximum
5 - 8.5
-
at pH 5 and 8.5: about 50% of activity maximum
5.5 - 9
-
recombinant monkey 5alpha-reductase isozyme 1
6.3 - 7.5
-
-
6.5 - 8.6
-
half maximal activity at pH 6.5 and 8.6
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
15 - 42
-
15C: about 50% of activity maximum, 42C: about 30% of activity maximum
21 - 37
-
21C: about 50% of activity maximum, 37C: about 70% of activity maximum
additional information
-
-
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
adrenal 5alpha-reductase expression is decreased in male withdrawal seizure-prone mice
Manually annotated by BRENDA team
-
from beard and axillary hair and frontal scalp hair
Manually annotated by BRENDA team
-
the enzyme is detected in biopsies of pelvic endometriosis
Manually annotated by BRENDA team
-
both type 1 and type 2 isoenzyme, copy number of mRNA and activity of type 1 isoenzyme is significantly higher than type 2
Manually annotated by BRENDA team
-
external
Manually annotated by BRENDA team
-
similar 5alpha-R1 mRNA expression in female and male rats, 5alpha-R2 mRNA expression significantly higher in females than in males
Manually annotated by BRENDA team
-
type 2 isoenzyme
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
additional information
-
nuclear and cell-debris fraction
-
Manually annotated by BRENDA team
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
24000
-
5alphaR2, immunoblotting
25000 - 35000
-
gel filtration
27000
-
SDS-PAGE; SDS-PAGE
42000
-
5alpha-reductase isoenzyme 2, SDS-PAGE, after treatment with O-glycosidase and neuraminidase a protein of a